Monday 26th – Tuesday 27th September 2011, Copthorne Tara Hotel, London

Biosimilars and Biobetters conference: Aligning business & science for success

Join SMi at their 2nd annual Biosimilars and Biobetters conference to be presented by leading industry figures and stakeholders. This event is an unmissable opportunity to gather vital information and contacts to work towards an optimal position in the biosimilars market.
At this conference you can expect to learn about a comprehensive range of pivotal issues in this area, the unique and exciting position of mAbs in this new arena, how Biobetters and Biosuperiors could challenge second generation biologics, and analysis of global biosimilars pricings structure.

Our fantastic line-up of speakers includes:

• Peter De Veene Deputy European Qualified Person for Pharmacovigilance Roche
• Anne Dollard Deputy General Counsel and Chief Patent Counsel Takeda
• Ross Lobell Vice President Regulatory Affairs MedImmune
• Richard DiCicco, Chairman Harvest Moon Pharmaceuticals
• Camilla Balleny Associate Intellectual Property Group Arnold & Porter
• Christopher Stothers Intellectual Property & Antitrust Litigation Counsel Arnold & Porter
• Harvinder Popli Director and Head In- Licensing Ranbaxy Labs
• Jean-Yves le Cotonnec Managing Partner, Founder & CEO TRISKEL Integrated Services S.A.
• Elisabeth Berthet Lawyer at the Paris Bar Armengaud-Guerlain
• Matthew Turner Global Medical Manager Sandoz Biopharmaceuticals

Plus many more!
ALSO! Two interactive post-conference workshops:

A) How Similar is Similar?
Hosted by: Peter Wittner, Senior Consultant, Interpharm Consultancy
Wednesday 28th September 2011
8.30pm – 12.30pm, Copthorne Tara Hotel

B) A Global View of Biosimilars: Regulatory Analysis and Pricing Structure Case Studies
Hosted By: Milena Izmirlieva, Senior Analyst, IHS Global Insight
Floriane Reinaud, Senior Analyst, IHS Global Insight
Wednesday 28th September 2011
1.30pm – 5.30pm, Copthorne Tara Hotel

Visit or alternatively contact Zain Philbey tel: +44 (0) 20 7827 6722 or email: